AI In Baseball: Oakland Ballers’ Bold Experiment In Data-Driven Decision Making

by THEFUTURE.TEAM

September 23, 2025

Reinventing The Game With Innovative Technology

In a move that echoes the clever maneuvers of iconic cultural moments, the Oakland Ballers have redefined the balance between tradition and modern analytics. Founded by edtech entrepreneur Paul Freedman, the team has leveraged the power of artificial intelligence to manage a game in real time—a daring experiment in a sport that is as much about data as it is about heart.

Embracing Data-Driven Decision Making

High-level baseball has long depended on granular statistics and data analytics, with teams employing experts to scrutinize every facet of the game. The Ballers, however, have elevated this approach by enlisting AI developed by Distillery and trained on over a century of baseball data, including the team’s own history. This system meticulously mirrored the strategic decisions of Ballers manager Aaron Miles—from pitching changes to lineup adjustments—demonstrating that even the nuanced aspects of baseball can be optimized through technology.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

Testing The Limits In A Minor League Setting

The minor league arena has historically served as a testbed for innovation. With the Oakland Ballers, experimentation extends beyond conventional boundaries. Past initiatives have included interactive, fan-driven managerial decisions, and now the integration of AI into active game management. This flexibility, championed by Freedman’s tech-savvy background, has provided a unique opportunity to experiment with cutting-edge technology long before it might be adopted in the major leagues.

Fan Reactions And The Cultural Divide

Despite the technical success of the AI-managed game, the initiative has struck a chord with Oakland fans. To many, the experiment reflects a broader cultural tension—a preference for preserving the soul of the sport over indiscriminate technological overreach. Detractors argue that prioritizing tech innovation over traditional fan engagement undermines the spirit of baseball, a critique that resonates deeply in a city that continues to grapple with the legacy of past franchise relocations.

Looking Ahead: The Future Of Ai And Baseball

While the AI experiment has now been shelved following mixed reactions, it has ignited a critical conversation about the balance between leveraging technology and maintaining authentic sporting tradition. Freedman acknowledges the backlash but remains optimistic about the ongoing dialogue. “The discussion about the pros and cons of this technology is valuable,” he observes, underscoring that AI is a tool to complement rather than replace human ingenuity in the game.

This bold experiment by the Oakland Ballers not only challenges conventional wisdom but also offers a glimpse into the transformative potential of advanced analytics in sports. As technology continues to evolve, so too will the debates about its impact on traditions cherished by fans and players alike.

The Future Forbes Realty Global Properties

Blood Proteins May Signal Prostate Cancer Risk More Than 15 Years Before Diagnosis

by THEFUTURE.TEAM

October 27, 2026

Distinctive proteins in men’s blood may offer clues to prostate cancer risk more than 15 years before a diagnosis, according to research from the University of Oxford. The findings could help scientists better understand why some prostate cancers become aggressive while others grow slowly and never cause serious harm.

Researchers analyzed blood samples from 2,555 men collected between 1992 and 2000. Of those participants, 982 were later diagnosed with prostate cancer; the remaining 1,573 served as a comparison group. The team measured more than 6,000 proteins in the samples, which had been collected years—and, in some cases, more than 15 years—before diagnosis.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

Protein Patterns Were Linked To Different Risks

The analysis identified proteins associated with prostate cancer risk overall, as well as proteins linked specifically to more aggressive or fast-growing forms of the disease. Higher levels of certain immune-system proteins, including GZMK and ANXA2, were associated with a lower long-term risk.

“Finding proteins linked to known prostate cancer driver genes in blood collected years before diagnosis gives us new insights into the earliest stages of the disease,” said Karl Smith-Byrne, the study’s corresponding author at Oxford.

The results, published in European Urology, are significant because prostate cancer is not a single, uniform disease. Many tumors grow slowly and may never threaten a patient’s health, while others progress rapidly and can be life-threatening. A clearer way to distinguish between these outcomes could eventually help improve how clinicians assess risk.

Promising Findings, Not A Screening Test

The researchers stressed that the protein patterns are not ready to be used as a screening test. The associations need further validation before they can inform clinical decisions, and the study does not establish that the proteins cause cancer or that measuring them can predict an individual’s outcome.

“Ultimately, we hope this will help us understand the biology of aggressive prostate cancer and identify markers that could improve how we assess risk in the future,” said first author Zhe Huang, a postdoctoral epidemiologist at Oxford Population Health.

Research Could Point To New Prevention Strategies

Prostate cancer is the most commonly diagnosed cancer among men in the European Union and the second most common worldwide, after lung cancer. In the EU, approximately 330,000 cases are diagnosed and 75,000 men die from the disease each year.

By identifying biological signals that appear long before diagnosis, the research may help scientists investigate the pathways involved in aggressive disease. Smith-Byrne said that, alongside existing and future genetic evidence, the findings could help reveal pathways that might ultimately be targeted to prevent aggressive prostate cancer.

Breaking news